99Z:F:F-MODUS THERAPEUTICS HLDG (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.0738

Change

0.00 (0.00)%

Market Cap

USD 3.15M

Volume

1.00K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-01 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOVA:F Novo Nordisk A/S

-1.00 (-0.81%)

USD 519.71B
VX1:F Vertex Pharmaceuticals Incorpo..

+0.15 (+0.04%)

USD 101.21B
RGO:F Regeneron Pharmaceuticals Inc

-6.20 (-0.69%)

USD 100.87B
CSJA:F CSL LTD SPON.ADR 2

+1.00 (+1.16%)

USD 81.84B
CSJ:F CSL Limited

+1.88 (+1.09%)

USD 81.66B
0QF:F Moderna Inc

+4.82 (+4.11%)

USD 46.57B
UNC0:F UCB S.A. UNSP.ADR 1/2

+1.50 (+2.54%)

USD 23.11B
UNC:F UCB SA

+2.20 (+1.83%)

USD 22.55B
1AEA:F argenx SE

+18.00 (+5.56%)

USD 21.64B
1AE:F Argen-X

+14.10 (+4.29%)

USD 21.38B

ETFs Containing 99Z:F

HAIL SPDR S&P Kensho Smart Mob.. 2.07 % 0.46 %

-0.14 (-0.66%)

USD 0.05B
DWMC 1.80 % 0.00 %

N/A

N/A
DWAS Invesco DWA SmallCap Mome.. 1.75 % 0.60 %

-1.00 (-0.66%)

USD 0.92B
IWC iShares Micro-Cap ETF 1.33 % 0.60 %

-0.65 (-0.66%)

USD 0.87B
FNY First Trust Mid Cap Growt.. 0.81 % 0.70 %

-0.89 (-0.66%)

USD 0.34B
ISMD Inspire Small/Mid Cap Imp.. 0.00 % 0.62 %

-0.24 (-0.66%)

USD 0.19B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -48.75% 11% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.75% 11% F 4% F
Trailing 12 Months  
Capital Gain -61.96% 20% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -61.96% 20% F 8% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -10.03% 39% F 19% F
Dividend Return -10.03% 39% F 17% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 20.06% 72% C 57% F
Risk Adjusted Return -49.99% 34% F 21% F
Market Capitalization 3.15M 8% B- 5% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.